Design and evaluation of oral formulation for apixaban

Design and evaluation of oral formulation for apixaban

Non-valvular atrial fibrillation (NVAF) is a common form of cardiac arrhythmia that affects 1–1.5% of adults and roughly 10% of elderly adults with dysphagia. Apixaban is an anticoagulant referred to as a factor Xa inhibitor, which has been shown to reduce the risk of stroke and systemic embolism in...

Full description

Bibliographic Details
Main Authors: Chien-Chiao Wang, Yu-Li Chen, Ta-Chien Lu, Catherine Lee, Yu-Chia Chang, Yen-Fan Chan, Philip Mathew, Xing-Rong Lin, Wen-Rung Hsieh, Ting-Yun Huang, Hsin-Lan Huang, Tsong-Long Hwang
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Heliyon
Subjects:
Apixaban
Oral disintegrating film
Non-valvular atrial fibrillation (NVAF)
Pharmacokinetics
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402305630X

Internet

http://www.sciencedirect.com/science/article/pii/S240584402305630X

Similar Items